Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 20 de 251 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RD, VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med 2019;380:6 de junio. [Ref.ID 103135]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
3. Cita con resumen
Young LA, Buse JB, Weaver MA, Vu MB, Mitchell M, Blakeney T, Grimm K, Rees J, Niblock F, Donahue KE, for the Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings. A randomized trial. JAMA Intern Med 2017;177:920-9. [Ref.ID 102017]
4.Enlace a cita original Cita con resumen
Anónimo. Actualización de insulinas. Infac: Información Farmacoterapéutica de la Comarca 2017;25:1-10. [Ref.ID 101631]
5. Cita con resumen
Flory J. Will cardiovascular outcomes data on newer diabetes drugs bury the older agents?. JAMA Intern Med 2017;177:301-2. [Ref.ID 101462]
6. Cita con resumen
Anónimo. Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017;59:19-21. [Ref.ID 101420]
7. Cita con resumen
Anónimo. An update on the "gliptins". Drug Ther Bull 2016;54:138-41. [Ref.ID 101014]
8. Cita con resumen
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2016:septiembre. [Ref.ID 100915]
9. Cita con resumen
Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Ali Abdelhamid Y, Anderson MB, Chapman MJ, Rayner CK, Deane AM. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med 2016;44:1842-50. [Ref.ID 100852]
10. Cita con resumen
Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SB, Cho Y, Nadeau-Fredette A-C, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GFM. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 2016;316:313-24. [Ref.ID 100498]
11. Cita con resumen
Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suárez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164:740-51. [Ref.ID 100415]
13. Cita con resumen
Lingvay I, Manghi FP, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen J, Buse JB, for the DUAL V Investigators. Effect of insulingGlargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes. The DUAL V randomized clinical trial. JAMA 2016;315:898-907. [Ref.ID 100023]
14. Cita con resumen
Anónimo. Insulin degludec (Tresiba) - A new long-acting insulin for diabetes. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:163-4. [Ref.ID 99817]
15. Cita con resumen
Anónimo. SGLT2 inhibitors: new reports. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:139-40. [Ref.ID 99811]
16. Cita con resumen
Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, Haller MJ, Raman S, Tamborlane WV, Coffey JK, SAenz AM, Beck RW, Nadeau KJ, for the T1D Exchange Clinic Network Metformin RCT Study Group. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 2015;314:2241-50. [Ref.ID 99792]
17. Cita con resumen
Ou S-M, Shih C-J, Chao P-W, Chu H, Kuo S-C, Lee Y-J, Wang S-J, Yang C-Y, Lin C-C, Chen T-J, Tarng D-C, Li S-Y, Chen Y-T. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 2015;163:663-72. [Ref.ID 99627]
18. Cita con resumen
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, for the TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42. [Ref.ID 99350]
20. Cita con resumen
Puig-Domingo M, Pellitero S. Nuevos agentes terapéuticos para la diabetes tipo 2. Med Clin (Barc) 2015;144:560-5. [Ref.ID 99167]
Seleccionar todas
 
 1 a 20 de 251 siguiente >>